Bajaj Healthcare begins production of Nimesulide API
Thane: Bajaj Healthcare Limited (BHL) a manufacturer of APIs, Intermediates and Formulations, has announced that the company has started commercial production of Nimesulide API at Plot No. N-92, MIDC, Tarapur.
"Nimesulide API" used for relief from pain and prevention of fever. BHL has received approval from FDA Maharashtra (India), to manufacture and market "Nimesulide API" as approved medication for pain relief and prevention of fever in India.
In FY21, the Company has acquired stressed assets from the Saraswat Cooperative Bank under SARFAESI Act, 2002, which comprises of three manufacturing units and one engineering unit at MIDC, Tarapur and having installed capacity of 111 MT per month. BHL has received an approval to start its commercial production in one of the manufacturing unit acquired under SARFAESI Act, 2002 at Plot No. N-92, MIDC, Tarapur.
Commenting on the "commencement of commercial production at Plot no. N 92, MIDC, Tarapur ", Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to start of commercial production at one of the manufacturing unit acquired under SARFAESI Act, 2002 from Saraswat Bank i.e. at Plot no. N 92, MIDC, Tarapur. This manufacturing unit has Installed Capacity of 40 MT/ p.m. BHL will start commercial production of Nimesulide API from 3rd September, 2021 onwards at Plot no. N 92, MIDC, Tarapur.
FDA Maharashtra (India), has granted permission to manufacture and sales the "Nimesulide API" in the domestic as well as in overseas market.
Read also: Bajaj Healthcare launches black fungus drug Posaconazole API for COVID patients
Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to Intermediates and 1 unit for formulation.
Next Story
